Devroey P, Mannaerts B, Smitz J, Coelingh Bennink H, Van Steirteghem A
Centre for Reproductive Medicine, Academisch Ziekenhuis, Vrije Universiteit Brussel, Belgium.
Hum Reprod. 1994 Jun;9(6):1064-9. doi: 10.1093/oxfordjournals.humrep.a138634.
In total, 50 couples participated in a pilot study evaluating the efficacy of various regimens of gonadotrophin-releasing hormone agonist (GnRHa) in association with recombinant human follicle-stimulating hormone (recFSH) in women undergoing in-vitro fertilization (IVF) and embryo transfer. The women were treated with recFSH alone (group I), or with recFSH in conjunction with pituitary desensitization using a buserelin intranasal spray, 4 x 150 micrograms per day, in a short protocol (group II) or in a long protocol (group III), or using triptorelin in a long protocol, giving a single dose of 3.75 mg i.m. (group IV) or daily s.c. injections of 200 micrograms (group V). In all women, treatment with recFSH resulted in multiple follicular growth and rises of serum inhibin and oestradiol. The latter indicates that the amount of remaining luteinizing hormone (LH) was sufficient to support FSH-induced oestrogen biosynthesis. On the day of human chorionic gonadotrophin (HCG) administration, endogenous LH was most profoundly suppressed in subjects treated with triptorelin. The median number of ampoules and treatment days required in the various treatment groups varied from 21 to 36 ampoules and from 7 to 14 days, respectively. The median number of oocytes per group ranged from 9 to 11 and all cumulus-corona-oocyte complexes, with the exception of two, were classified as mature. The median fertilization and cleavage rates ranged between the treatment groups from 40 to 73% and from 73 to 100%, respectively. Fertilization failure of retrieved oocytes occurred in six couples with andrological or unexplained infertility. One patient had no transfer because of insufficient embryo quality.(ABSTRACT TRUNCATED AT 250 WORDS)
共有50对夫妇参与了一项初步研究，该研究评估了促性腺激素释放激素激动剂（GnRHa）的各种方案与重组人促卵泡生成素（recFSH）联合使用，对接受体外受精（IVF）和胚胎移植的女性的疗效。这些女性分别接受单独的recFSH治疗（第一组），或使用布舍瑞林鼻喷雾剂进行垂体脱敏联合recFSH治疗，短方案（第二组）每天4次，每次150微克，或长方案（第三组），或使用曲普瑞林进行长方案治疗，肌肉注射单剂量3.75毫克（第四组）或每天皮下注射200微克（第五组）。对所有女性而言，recFSH治疗均导致多个卵泡生长以及血清抑制素和雌二醇水平升高。后者表明剩余促黄体生成素（LH）的量足以支持FSH诱导的雌激素生物合成。在注射人绒毛膜促性腺激素（HCG）当天，使用曲普瑞林治疗的受试者体内内源性LH受到的抑制最为显著。各治疗组所需的安瓿中位数数量和治疗天数分别为21至36支安瓿和7至14天。每组卵母细胞的中位数数量为9至11个，除两个外，所有卵丘-放射冠-卵母细胞复合体均被分类为成熟。各治疗组的受精率和卵裂率中位数分别在40%至73%和73%至100%之间。6对患有男性因素或不明原因不孕症的夫妇出现了取到的卵母细胞受精失败的情况。1名患者因胚胎质量不佳未进行移植。（摘要截取自250字）
